Burnham to reset expectations of NHS

Shadow Health secretary, Andy Burnham, addresses deletes at the Labour party conference in Manchester this morning.
©Charlie Bibby

Shadow health secretary says people must be more realistic

Merck: Confusion mounts over shared name

German drugmaker seeks to defend rights to brand

Merck seeks the right alchemy for growth

Centuries-old drugmaker builds buffers against volatility

Small-cap Week, May 2

SkyePharma, Xeros, Naibu and Focusrite featured

Apple targets ‘silver surfers’ with iPad

Modified tablet for Japan to tap into the ageing population

A worker at Sanofi's dengue vaccine plant in Neuville-sur-Saone, France is seen in this undated handout image released to the media on Friday, Aug. 2, 2013. Sanofi is making the first batches of a dengue vaccine at its new 300 million-euro ($398 million) plant, even as it waits for results next year of make-or-break trials to determine whether the product will be a $2.6 billion-a-year success or an $800 million flop. Photographer: Vincent Moncorge/Sanofi via Bloomberg --------------------------------------------- A lab technician first inspects tissue samples with the naked eye. The tumor samples then undergo additional analytical tests.

Weak euro lifts European drugmakers

Sanofi and Bayer report strong first quarter and raise forecasts

Valeant: scoreboard watching

Stock price has shone under heavy scrutiny

Perrigo rebuffs Mylan’s sweetened offer

Generic drugs group increases bid amid three-way takeover battle

Marijuana leaf cannabis plant
©Vladyslav Danilin/Dreamstime

Medicinal cannabis group seeks $180m

GW Pharmaceuticals turns to Nasdaq for anti-epilepsy drug funding

ECJ backs bans on donated gay blood

Court rules ban on gay men donating blood can ‘minimise’ risk of HIV

Takeda to pay $2.7bn to settle over Actos

Japanese pharma group to pay out cancer claims for diabetes drug

GSK reveals strong trial results for shingles drug

UK drugmaker prepares to update investors on R&D pipeline

Pfizer cuts forecasts on strong dollar

Drugmaker hit by currency headwinds while Merck is spared

Mylan rounds on Teva as it rejects bid

Group spurns offer from Israeli rival in three-way takeover fight

No end in sight to wave of pharma dealmaking

Deals driven by cheap capital and race to develop new treatments

Clinigen set to lead unlicensed drugs market

UK pharma distributor sees £225m deal boost

Small-cap Week, April 25

Shoe Zone warns on lower average selling prices

Three-way drugs merger battle hots up

Perrigo rejects formal offer from bigger rival Mylan

AstraZeneca forced to defend Celgene deal

Drugmaker accused of trading future growth for short-term gains

Scientists target people and mosquitoes

The first malaria vaccine will be a milestone but not a magic bullet


More FT Twitter accounts